Concepts (252)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder, Neurogenic | 1 | 2023 | 47 | 0.800 |
Why?
|
| Carcinoma, Renal Cell | 9 | 2006 | 253 | 0.790 |
Why?
|
| Bacteriuria | 1 | 2023 | 83 | 0.760 |
Why?
|
| Kidney Neoplasms | 10 | 2006 | 461 | 0.720 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2023 | 166 | 0.690 |
Why?
|
| Vesico-Ureteral Reflux | 5 | 2023 | 82 | 0.640 |
Why?
|
| Ureteral Obstruction | 4 | 2023 | 109 | 0.620 |
Why?
|
| Urinary Tract Infections | 1 | 2023 | 307 | 0.610 |
Why?
|
| Ureteroscopy | 3 | 2025 | 20 | 0.590 |
Why?
|
| Cryosurgery | 4 | 2005 | 49 | 0.550 |
Why?
|
| Ureter | 4 | 2023 | 100 | 0.550 |
Why?
|
| Nephrectomy | 4 | 2018 | 182 | 0.520 |
Why?
|
| Kidney Calculi | 2 | 2025 | 47 | 0.460 |
Why?
|
| Kidney Pelvis | 3 | 2021 | 46 | 0.460 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2016 | 223 | 0.430 |
Why?
|
| Hypospadias | 3 | 2020 | 80 | 0.420 |
Why?
|
| Kidney | 2 | 2016 | 1421 | 0.370 |
Why?
|
| Adrenal Hyperplasia, Congenital | 2 | 2008 | 35 | 0.340 |
Why?
|
| Neonatal Screening | 3 | 2008 | 193 | 0.340 |
Why?
|
| Urology | 2 | 2018 | 86 | 0.330 |
Why?
|
| Serum | 1 | 2010 | 46 | 0.320 |
Why?
|
| Blood Specimen Collection | 1 | 2010 | 49 | 0.320 |
Why?
|
| Blood Chemical Analysis | 1 | 2010 | 88 | 0.320 |
Why?
|
| Carbon | 1 | 2010 | 98 | 0.310 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 2196 | 0.310 |
Why?
|
| Prostate | 2 | 2017 | 449 | 0.300 |
Why?
|
| Urethral Diseases | 2 | 2020 | 19 | 0.300 |
Why?
|
| Postoperative Complications | 5 | 2023 | 3177 | 0.290 |
Why?
|
| Cortodoxone | 1 | 2007 | 4 | 0.280 |
Why?
|
| 17-alpha-Hydroxyprogesterone | 1 | 2007 | 9 | 0.270 |
Why?
|
| Bile Acids and Salts | 1 | 2010 | 259 | 0.270 |
Why?
|
| Laparoscopy | 4 | 2018 | 520 | 0.270 |
Why?
|
| Penis | 2 | 2020 | 102 | 0.270 |
Why?
|
| Ureteral Calculi | 1 | 2025 | 16 | 0.240 |
Why?
|
| Nephrolithotomy, Percutaneous | 1 | 2025 | 5 | 0.240 |
Why?
|
| Kidney Tubules, Collecting | 1 | 2005 | 8 | 0.240 |
Why?
|
| Lithotripsy | 1 | 2025 | 27 | 0.240 |
Why?
|
| Catheter Ablation | 2 | 2005 | 246 | 0.230 |
Why?
|
| Child | 18 | 2025 | 25843 | 0.230 |
Why?
|
| Kidney Transplantation | 2 | 2023 | 689 | 0.230 |
Why?
|
| Retrospective Studies | 15 | 2023 | 17518 | 0.220 |
Why?
|
| Documentation | 2 | 2022 | 122 | 0.210 |
Why?
|
| Infant | 16 | 2022 | 13201 | 0.210 |
Why?
|
| Urologic Neoplasms | 1 | 2003 | 38 | 0.210 |
Why?
|
| Urinalysis | 1 | 2023 | 66 | 0.200 |
Why?
|
| Hydronephrosis | 3 | 2021 | 38 | 0.180 |
Why?
|
| Humans | 40 | 2025 | 134085 | 0.180 |
Why?
|
| Penile Diseases | 1 | 2020 | 11 | 0.180 |
Why?
|
| Urinary Fistula | 1 | 2020 | 20 | 0.170 |
Why?
|
| Hospitals, Pediatric | 3 | 2020 | 791 | 0.170 |
Why?
|
| Cutaneous Fistula | 1 | 2020 | 23 | 0.170 |
Why?
|
| Male | 27 | 2025 | 66057 | 0.170 |
Why?
|
| Reoperation | 3 | 2020 | 856 | 0.170 |
Why?
|
| Treatment Outcome | 12 | 2025 | 13051 | 0.170 |
Why?
|
| Urologic Surgical Procedures | 4 | 2021 | 59 | 0.160 |
Why?
|
| Anesthetics | 1 | 2020 | 80 | 0.160 |
Why?
|
| Nerve Block | 1 | 2020 | 69 | 0.160 |
Why?
|
| Child, Preschool | 13 | 2023 | 14838 | 0.160 |
Why?
|
| Urogenital System | 1 | 2019 | 35 | 0.160 |
Why?
|
| Adolescent | 11 | 2025 | 20601 | 0.150 |
Why?
|
| Equipment Design | 2 | 2018 | 606 | 0.150 |
Why?
|
| Child Health | 1 | 2019 | 68 | 0.150 |
Why?
|
| Pediatricians | 1 | 2019 | 71 | 0.150 |
Why?
|
| Physical Examination | 1 | 2019 | 165 | 0.140 |
Why?
|
| Pediatrics | 2 | 2018 | 1215 | 0.140 |
Why?
|
| Physicians, Women | 1 | 2018 | 52 | 0.140 |
Why?
|
| Anesthesia | 1 | 2020 | 213 | 0.140 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2010 | 294 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 772 | 0.140 |
Why?
|
| Prostatic Diseases | 1 | 2017 | 15 | 0.140 |
Why?
|
| Engineering | 1 | 2017 | 7 | 0.140 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2016 | 21 | 0.130 |
Why?
|
| Female | 21 | 2025 | 71851 | 0.130 |
Why?
|
| Hematuria | 1 | 2016 | 55 | 0.130 |
Why?
|
| Spermatic Cord Torsion | 1 | 2016 | 15 | 0.130 |
Why?
|
| Cystitis | 1 | 2016 | 51 | 0.120 |
Why?
|
| Abscess | 1 | 2017 | 140 | 0.120 |
Why?
|
| Specialties, Surgical | 1 | 2017 | 82 | 0.120 |
Why?
|
| Operating Rooms | 1 | 2016 | 75 | 0.120 |
Why?
|
| Carbonic Anhydrases | 2 | 2006 | 26 | 0.120 |
Why?
|
| Urethra | 1 | 2015 | 90 | 0.120 |
Why?
|
| Injury Severity Score | 1 | 2016 | 230 | 0.120 |
Why?
|
| Foreskin | 1 | 2015 | 4 | 0.120 |
Why?
|
| Anti-Retroviral Agents | 1 | 2016 | 150 | 0.120 |
Why?
|
| Patient Transfer | 1 | 2016 | 110 | 0.120 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 314 | 0.120 |
Why?
|
| Hydrocolpos | 1 | 2014 | 2 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2022 | 796 | 0.120 |
Why?
|
| Treatment Failure | 1 | 2016 | 367 | 0.110 |
Why?
|
| Ureterocele | 1 | 2014 | 4 | 0.110 |
Why?
|
| Skin Transplantation | 1 | 2015 | 59 | 0.110 |
Why?
|
| Infant, Newborn | 8 | 2018 | 8607 | 0.110 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 230 | 0.110 |
Why?
|
| Urogenital Abnormalities | 1 | 2016 | 160 | 0.110 |
Why?
|
| Robotic Surgical Procedures | 1 | 2018 | 232 | 0.110 |
Why?
|
| Bone Marrow Transplantation | 1 | 2016 | 620 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 717 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 2573 | 0.100 |
Why?
|
| Renal Insufficiency | 1 | 2015 | 254 | 0.100 |
Why?
|
| Models, Animal | 2 | 2005 | 486 | 0.100 |
Why?
|
| Surgical Flaps | 1 | 2015 | 196 | 0.100 |
Why?
|
| Ultrasonic Therapy | 2 | 2003 | 29 | 0.100 |
Why?
|
| Incidence | 5 | 2020 | 3414 | 0.090 |
Why?
|
| Staphylococcal Infections | 1 | 2017 | 573 | 0.090 |
Why?
|
| Chromatography, Liquid | 2 | 2010 | 245 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1019 | 0.090 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2003 | 195 | 0.090 |
Why?
|
| Feasibility Studies | 2 | 2022 | 820 | 0.090 |
Why?
|
| Galactosemias | 1 | 2010 | 15 | 0.080 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2010 | 38 | 0.080 |
Why?
|
| Peroxisomal Disorders | 1 | 2010 | 18 | 0.080 |
Why?
|
| Operative Time | 2 | 2020 | 189 | 0.070 |
Why?
|
| Steroid 11-beta-Hydroxylase | 1 | 2008 | 1 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 1155 | 0.070 |
Why?
|
| Linear Models | 1 | 2010 | 723 | 0.070 |
Why?
|
| Androstenedione | 1 | 2007 | 16 | 0.070 |
Why?
|
| Calibration | 1 | 2007 | 100 | 0.070 |
Why?
|
| False Positive Reactions | 1 | 2007 | 146 | 0.070 |
Why?
|
| Wound Healing | 2 | 2015 | 488 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2016 | 3729 | 0.070 |
Why?
|
| Biliary Atresia | 1 | 2010 | 206 | 0.070 |
Why?
|
| Hydrocortisone | 1 | 2007 | 246 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2007 | 363 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2022 | 1250 | 0.060 |
Why?
|
| Kidney Calices | 1 | 2005 | 4 | 0.060 |
Why?
|
| Kidney Cortex | 1 | 2005 | 20 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3487 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2025 | 6602 | 0.060 |
Why?
|
| United States | 4 | 2025 | 11750 | 0.060 |
Why?
|
| Needles | 1 | 2005 | 52 | 0.060 |
Why?
|
| Hot Temperature | 1 | 2005 | 148 | 0.060 |
Why?
|
| Oxidoreductases | 1 | 2005 | 103 | 0.060 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2004 | 25 | 0.060 |
Why?
|
| Necrosis | 1 | 2005 | 221 | 0.060 |
Why?
|
| Safety | 1 | 2005 | 217 | 0.060 |
Why?
|
| Surgeons | 2 | 2020 | 284 | 0.060 |
Why?
|
| Canada | 1 | 2025 | 346 | 0.060 |
Why?
|
| Young Adult | 3 | 2025 | 9917 | 0.060 |
Why?
|
| Dogs | 1 | 2005 | 798 | 0.050 |
Why?
|
| Time Factors | 2 | 2015 | 6604 | 0.050 |
Why?
|
| Cysts | 1 | 2004 | 104 | 0.050 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 39 | 0.050 |
Why?
|
| Prognosis | 5 | 2016 | 5085 | 0.050 |
Why?
|
| Syphilis, Congenital | 1 | 2003 | 30 | 0.050 |
Why?
|
| Ultrasonography, Interventional | 1 | 2005 | 205 | 0.050 |
Why?
|
| Survival Rate | 4 | 2016 | 2218 | 0.050 |
Why?
|
| Laser Therapy | 1 | 2005 | 227 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2020 | 5206 | 0.050 |
Why?
|
| Quality Improvement | 2 | 2020 | 700 | 0.050 |
Why?
|
| Cancer Vaccines | 1 | 2004 | 190 | 0.050 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2003 | 82 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2003 | 307 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2005 | 522 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2023 | 239 | 0.050 |
Why?
|
| Monocytes | 1 | 2004 | 360 | 0.050 |
Why?
|
| Fatty Acid Desaturases | 1 | 2001 | 9 | 0.050 |
Why?
|
| Infant, Premature | 1 | 2007 | 858 | 0.050 |
Why?
|
| Swine | 1 | 2005 | 1218 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2005 | 513 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2004 | 610 | 0.040 |
Why?
|
| Training Support | 1 | 2020 | 19 | 0.040 |
Why?
|
| Nurse Anesthetists | 1 | 2020 | 13 | 0.040 |
Why?
|
| Sacrococcygeal Region | 1 | 2020 | 35 | 0.040 |
Why?
|
| Anesthesia, Caudal | 1 | 2020 | 15 | 0.040 |
Why?
|
| Anesthesiologists | 1 | 2020 | 39 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2007 | 3043 | 0.040 |
Why?
|
| Pulmonary Alveoli | 1 | 2020 | 142 | 0.040 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2001 | 121 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2003 | 510 | 0.040 |
Why?
|
| Neoplasm Staging | 4 | 2004 | 1389 | 0.040 |
Why?
|
| Genitalia, Male | 1 | 2019 | 39 | 0.040 |
Why?
|
| Bone Neoplasms | 1 | 2003 | 447 | 0.040 |
Why?
|
| Patient Selection | 1 | 2003 | 735 | 0.040 |
Why?
|
| Recurrence | 2 | 2018 | 1472 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2022 | 415 | 0.040 |
Why?
|
| Dextrans | 1 | 2018 | 47 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 268 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2018 | 331 | 0.030 |
Why?
|
| Hyaluronic Acid | 1 | 2018 | 109 | 0.030 |
Why?
|
| Texas | 2 | 2016 | 3715 | 0.030 |
Why?
|
| Career Choice | 1 | 2018 | 163 | 0.030 |
Why?
|
| Administration, Intravesical | 1 | 2016 | 33 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2018 | 152 | 0.030 |
Why?
|
| PAX2 Transcription Factor | 1 | 2016 | 27 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2016 | 30 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2003 | 1317 | 0.030 |
Why?
|
| Mentors | 1 | 2018 | 160 | 0.030 |
Why?
|
| Cicatrix | 1 | 2018 | 128 | 0.030 |
Why?
|
| Cystoscopy | 1 | 2016 | 46 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2016 | 78 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2005 | 1721 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 5477 | 0.030 |
Why?
|
| Program Development | 1 | 2017 | 190 | 0.030 |
Why?
|
| Morbidity | 1 | 2016 | 256 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 4806 | 0.030 |
Why?
|
| Mentoring | 1 | 2017 | 82 | 0.030 |
Why?
|
| Self Report | 1 | 2018 | 553 | 0.030 |
Why?
|
| Animals | 3 | 2006 | 36543 | 0.030 |
Why?
|
| Colpotomy | 1 | 2014 | 7 | 0.030 |
Why?
|
| Triage | 1 | 2016 | 148 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 507 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 389 | 0.030 |
Why?
|
| Health Facilities | 1 | 2014 | 66 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 2017 | 279 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2003 | 1409 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 592 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2003 | 1786 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2003 | 1417 | 0.030 |
Why?
|
| Pedigree | 1 | 2016 | 1698 | 0.020 |
Why?
|
| Germany | 2 | 2003 | 60 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2004 | 972 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2016 | 1492 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2016 | 871 | 0.020 |
Why?
|
| Risk Factors | 2 | 2016 | 11166 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 567 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2020 | 1250 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 1343 | 0.020 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 811 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 2264 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2934 | 0.020 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2006 | 13 | 0.020 |
Why?
|
| Middle Aged | 5 | 2005 | 29402 | 0.020 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2004 | 18 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 1088 | 0.010 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2003 | 15 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2004 | 225 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2004 | 361 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 3854 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2004 | 912 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2004 | 358 | 0.010 |
Why?
|
| Aged | 3 | 2005 | 21756 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2004 | 1140 | 0.010 |
Why?
|
| Acyl-CoA Dehydrogenase | 1 | 2001 | 5 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2004 | 837 | 0.010 |
Why?
|
| Antibodies, Bacterial | 1 | 2003 | 407 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 1071 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2003 | 505 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2003 | 673 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 1599 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 1764 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2004 | 970 | 0.010 |
Why?
|
| Adult | 3 | 2005 | 31964 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2004 | 753 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 1400 | 0.010 |
Why?
|
| Algorithms | 1 | 2003 | 1736 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 3797 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 1814 | 0.010 |
Why?
|
| Mass Screening | 1 | 2001 | 840 | 0.010 |
Why?
|
| Phenotype | 1 | 2004 | 4556 | 0.010 |
Why?
|
| Mutation | 1 | 2008 | 6305 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2004 | 7207 | 0.010 |
Why?
|
| Mice | 1 | 2006 | 19044 | 0.000 |
Why?
|